araag2/HINT huggingface dataset:
Clinical trial NCT00445484 (phase 2, status: completed)
Conditions: multiple myeloma and plasma cell neoplasm
ICD codes: C96.20, C96.29, D47.09
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma (MM) meeting all of the following criteria:

               -  Relapsed or refractory disease

               -  Previously received ≥ 2 courses of antimyeloma treatment

          -  Measurable levels of myeloma paraprotein in serum (> 0.5 g/dL) or urine (> 0.2
             g/24-hour urine collection) OR serum-free light-chain disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Creatinine ≤ 2.5 mg/dL

          -  Bilirubin ≤ 2.0 mg/dL

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of highly effective contraception ≥ 4 weeks
             before, during, and for 4 weeks after completion of study therapy

          -  No other malignancy within the past 5 years except treated basal cell or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix or breast

          -  No serious medical condition, laboratory abnormality, or psychiatric illness that
             would preclude study treatment or put patient at unacceptable risk

          -  No known hypersensitivity to thalidomide or lenalidomide

               -  No development of erythema nodosum in the presence of a reaction characterized by
                  a desquamating rash while taking thalidomide or similar drugs

          -  No known hypersensitivity to any component of the pneumococcal polyvalent vaccine,
             including diphtheria toxin or CRM 197

          -  No known HIV positivity

          -  No infectious hepatitis type A, B, or C

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 3 prior treatment regimens for MM

          -  More than 6 months since prior lenalidomide

          -  More than 28 days since prior experimental drug or therapy

          -  More than 1 month since prior systemic antimyeloma therapy

          -  More than 1 month since prior and no concurrent systemic corticosteroids

          -  No other concurrent anticancer agents or treatments or investigational agents

          -  No concurrent thalidomide

          -  No concurrent radiotherapy

          -  No other concurrent immune therapy or immunomodulatory agents
Clinical trial NCT00612183 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma, mantle cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bendamustine hydrochloride
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

        Non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below.
        No restrictions regarding gender.

          -  Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's
             lymphoma or mantle cell lymphoma.

          -  Patients who had not received treatment for at least 4 weeks (for at least 12 weeks in
             the case of antibody therapy) after completion of prior therapy and who are judged to
             carry no effect from the prior therapy.

          -  Patients aged from 20 to less than 75 years.

          -  Performance Status (P.S.): 0 or 1.

          -  Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung,
             liver, and kidney functions).

          -  Patients from whom written consent to participate in this study has been obtained.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded.

          -  Patients with apparent infections.

          -  Patients with serious complications (hepatic failure or renal failure).

          -  Patients with complication or history of serious heart failure (e.g. cardiac
             infarction, ischemic heart disease).

          -  Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea).

          -  Patients who are known to be positive for HBV, HCV or HIC.

          -  Patients receiving other investigational drugs within 3 months before registration in
             the study.

          -  Patients with allogenic bone-marrow transplant.

          -  Women who are pregnant, of childbearing potential, or lactating.

          -  Patients who do not agree to contraception.

          -  Otherwise, patients who are judged by the investigator as being unsuitable for
             inclusion in the study.
Clinical trial NCT01627782 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, ketamine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Be medically stable on the basis of clinical laboratory tests performed at screening

          -  Meet diagnostic criteria for recurrent major depressive disorder (MDD), without
             psychotic features

          -  Have a history of inadequate response, ie treatment was not successful, to at least 1
             antidepressant

          -  Have an Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) total
             score >= 40 at screening and predose at Day 1

          -  Inpatient or agreed to be admitted to the clinic on each dosing day

        Exclusion Criteria:

          -  Has uncontrolled hypertension

          -  Has a history of, or current signs and symptoms of diseases, infections or conditions
             that in the opinion of the investigator, would make participation not be in the best
             interest (eg, compromise the well-being) of the patient or that could prevent, limit,
             or confound the protocol-specified assessments

          -  Has known allergies, hypersensitivity, or intolerance to ketamine or its excipients

          -  Is unable to read and understand the consent forms and patient reported outcomes,
             complete study-related procedures, and/or communicate with the study staff
Clinical trial NCT00113516 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, paclitaxel, sunitinib
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven NSCLC

          -  Stage IIIB (locally advanced with malignant effusion) or Stage IV disease

          -  No prior therapy for NSCLC

          -  Evidence of unidimensionally measurable disease

        Exclusion Criteria:

          -  Previous treatment with systemic chemotherapy for lung cancer

          -  History of or known brain metastases

          -  NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment

          -  Evidence of hemoptysis within 4 weeks of starting study treatment

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality

          -  Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors
             of EGFR and PDGFR
Clinical trial NCT00343239 (phase 2, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: docetaxel, cisplatin, fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven gastric adenocarcinoma diagnosis

          -  Selected Stage IIB (T3N0M0), Stage IIIA (T2aN2M0, T2bN2M0, T3N1M0, T4N0M0), Stage IIIB
             (T3N2M0) and selected Stage IV (all T4 , NM0, all TN3M0's). Clinical staging performed
             with endoscopic ultrasound and CT. Laparotomy or laparoscopy is preferred to determine
             resectability and peritoneal involvement.

          -  ECOG performance status between 0 and 2

          -  Acceptable hematological profile :

               -  WBC (White Blood Cell) count ≥4000/mm3

               -  Platelet count ≥100 000 mm3

               -  Hemoglobin ≥9 g/100 mL (if lower, may be included following transfusion)

          -  Adequate renal function

               -  Serum creatinine <1.2 mg/dl or calculated creatinine clearance in 24-hours urine
                  >60 mL/min.

          -  Adequate hepatic function

               -  Bilirubin < UNL

               -  Transaminases (ALT, AST) <2.5 x UNL

               -  Alcaline phosphatase <2.5 x UNL

          -  Adequate pulmonary function

          -  Adequate cardiac function

          -  No prior chemotherapy for gastric cancer

        Exclusion Criteria:

          -  Other histological types of gastric cancer (leiomyosarcoma, lymphoma) than
             adenocarcinoma

          -  Pregnant or lactating patients

          -  Patients with brain, bone or other metastases; peritoneal involvement

          -  Other serious underlying medical conditions which could impair the ability of the
             patient to participate in the study (congestive heart failure, serious arrhythmia,
             uncontrolled diabetes mellitus, serious neuropathy), history of myocardial infarction
             within 6 months prior to study entry

          -  Previous or other current malignancies, with the exception of carcinoma of the cervix
             uteri or breast cancer or basal cell skin cancer and a disease-free period shorter
             than 5 years

          -  Active infection and other serious disease

          -  Any other experimental drugs within a 4-week period prior to the study

          -  Contraindications for the use of any study drug (e.g. history of hypersensitivity to
             the contents of the study drugs)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00192036 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Inoperable non small cell lung cancer Stage III

          -  Adequate hematological parameters

          -  Adequate Lung function reserve

        Exclusion Criteria:

          -  Previous chemotherapy and thoracic radiation for non small cell lung cancer

          -  Presence of distant metastases
Clinical trial NCT00316212 (phase 2, status: terminated)
Conditions: coronary disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: ins50589 intravenous infusion
SMILES: [H][C@]12O[C@@H](O[C@@]1([H])[C@@H](O[C@@H]2COP(O)(O)=O)N1C=NC2=C1N=CN=C2NC(=O)NCC)\C=C\C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Are scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass

          -  Willing to receive allogeneic blood product transfusions during and after surgery

        Exclusion Criteria:

          -  Have had previous cardiac surgery

          -  Have had previous median sternotomy

          -  Have tendency for bleeding or family history of bleeding

          -  Have an abnormally low platelet count

          -  Have received certain anticoagulant or antiplatelet medications within a specified
             time period prior to the scheduled CABG surgery
Clinical trial NCT00356525 (phase 2, status: terminated)
Conditions: lung neoplasms
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, gemcitabine, carboplatin, pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    stopped early due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  You have non-small cell lung cancer that has come back (relapsed) after initial
             treatment with surgery and chemotherapy.

          -  You have good kidney, liver, and bone marrow organ function.

          -  You are fully active or able to carry out light work such as housework or office work.

        Exclusion Criteria:

          -  You have received pemetrexed or gemcitabine in the past for lung cancer

          -  You are currently receiving another treatment for your relapsed lung cancer, or have
             had chemotherapy or certain other therapies for relapsed lung cancer in the past

          -  You are unable to take corticosteroid drugs like dexamethasone

          -  You are unable or unwilling to take the folic acid pills or Vitamin B12 injections
             that are required for the study

          -  You are unable to stop taking aspirin or other drugs that control inflammation for
             certain periods of time during the study

          -  You have had a heart attack in the last 6 months, or have other heart problems that
             are not controlled with medication
Clinical trial NCT01057667 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: ro5024048, ribavirin [copegus], peginterferon alfa-2a [pegasys]
SMILES: CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-70 years of age

          -  hepatitis C, genotype 1 or 4, of over 6 months duration

          -  treatment-naïve

          -  negative pregnancy test; female patients of childbearing age and male patients with
             female partners of childbearing age must use two forms of contraception during
             treatment and following the last dose of ribavirin in accordance with locally approved
             label for ribavirin

        Exclusion Criteria:

          -  pregnant or breast feeding females or male partners of pregnant females

          -  previous interferon or ribavirin based therapy or investigational anti-HCV agent

          -  systemic antiviral therapy with established or perceived activity against HCV </=3
             months prior to first dose of study drug

          -  hepatitis A or B, or HIV infection

          -  history or evidence of medical condition associated with chronic liver disease other
             than HCV
Clinical trial NCT00422032 (phase 2, status: completed)
Conditions: myelodysplastic syndrome, leukemia
ICD codes: D46.9, D46.C, D46.Z, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with MDS and >/= 5% blasts or International Prognostic Scoring System (IPSS)
             risk intermediate or high; patients with Chronic Myelomonocytic Leukemia (CMML).

          2. No prior intensive chemotherapy or high-dose ara-C (> 1g/m2).

          3. Prior biologic therapies, targeted therapies, or single agent chemotherapy allowed.

          4. Patients must have been off chemotherapy for 2 weeks prior to entering this study and
             recovered from the toxic effects of that therapy, unless there is evidence of rapidly
             progressive disease.

          5. Hydroxyurea is permitted for control of counts prior to treatment.

          6. Procrit, GCSF are allowed before therapy.

          7. Performance 0-2 (Eastern Cooperative Oncology Group (ECOG)). Adequate organ function
             including the following: Adequate liver function (bilirubin of < 2mg/dl), and renal
             function (creatinine < 2mg/dl), and SGPT (ALT) < 3 * upper limit of normal (ULN).
             Adequate cardiac functions (New York Heart Association (NYHA) cardiac III-IV
             excluded).

          8. Signed informed consent.

        Exclusion Criteria:

          1. Nursing and pregnant females. Patients of childbearing potential should practice
             effective methods of contraception. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          2. Active and uncontrolled infections.

          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          4. Prior clofarabine treatment.
Clinical trial NCT00320190 (phase 2, status: terminated)
Conditions: leukemia, myeloid, chronic
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: imatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    terminated due to slow participant accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic phase Ph^+ chronic myeloid leukemia (CML) demonstrating only a suboptimal
             response, defined as a hematologic response that is less than a complete hematologic
             response after at least 3 months of monotherapy with imatinib, 400 mg; a cytogenic
             response (CgR) that is less than a partial CgR (PCgR) after at least 6 months of
             monotherapy with imatinib, 400 mg; a PCgR after at least 12 months of monotherapy with
             imatinib, 400 mg; or less than a major molecular response with a complete CgR after at
             least 18 months of monotherapy with imatinib, 400 mg.

          -  Either gender

          -  Age of 18 years or older

        Exclusion Criteria:

          -  Previous diagnosis of accelerated phase or blast crisis CML

          -  Uncontrolled or significant cardiovascular disease

          -  History of significant bleeding disorder unrelated to CML

          -  Concurrent malignancies

          -  Intolerance of imatinib, 400 mg

          -  Prior treatment with imatinib at a dose higher than 400 mg

          -  Prior stem cell transplantation and/or high-dose chemotherapy for CML
Clinical trial NCT00294762 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: tarceva, carboplatin, paclitaxel
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Age >= 18

          -  Histologically or cytologically documented non-small cell lung cancer (NSCLC)

          -  Eastern Cooperative Oncology Group (ECOG)performance status (PS)0, 1, 2

          -  Radiologically measurable or evaluable disease No prior chemotherapy

          -  1 or 2 epithelial growth factor receptor (EGFR) pathway markers positive at screening

          -  Tumor tissue block or fine needle aspirate

        Exclusion Criteria:

          -  Any concurrent anticancer therapy or radiation

          -  Other active malignancy

          -  Uncontrolled brain metastases

          -  GI abnormalities

          -  Severe abnormalities of the cornea

          -  Significant cardiac disease

          -  Active infection
Clinical trial NCT00699296 (phase 2, status: terminated)
Conditions: cutaneous t-cell lymphoma, leukemia-lymphoma, adult t-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: panobinostat (lbh589)
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Eligibility criteria:

        Inclusion criteria:

          -  CTCL: Biopsy-confirmed MF or SS stages IB-IVA2.

          -  Patients who have SS with bone marrow involvement are also eligible.

          -  Patients with transformed CTCL are eligible.

          -  ATL: Patient with cytologically or histopathologically confirmed lymphoma.

          -  Lymphoma should be identified as tumors derived peripheral T-cells by cell surface
             marker.

          -  ATL: Patients with positivity for anti-HTLV-1 antibody

          -  Patients must have received at least two systemic therapy regimens.

          -  Patients must have had disease progression on or following their most recent treatment
             regimen.

          -  Age ≥ 20 years

          -  ECOG Performance Status of ≤ 2

          -  Written informed consent obtained prior to any study specific screening procedures

        Exclusion criteria:

          -  Patients with a history of primary CNS tumors

          -  Any history or presence of brain metastases

          -  Patients with any peripheral neuropathy ≥ CTCAE grade 2

          -  Patients with unresolved diarrhea > CTCAE grade 1

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral LBH589

          -  Patients with concurrent severe and/or uncontrolled liver or renal disease

          -  Patients using sodium valproate ≤5 days prior to starting study drug

          -  Patients with an active bleeding diathesis or on any treatment with therapeutic doses
             of sodium warfarin or other antivitamin K drugs

          -  Patients who have received any investigational drug or chemotherapy or undergone major
             surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side
             effects of such therapy

          -  Patients who have received biologic therapy, target therapy (e.g. denileukin diftitix
             ), vaccine, systemic steroids or immunotherapy ≤ 2 weeks prior to starting study
             treatment or who have not recovered from side effects of such therapy

          -  Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy